Xolair May Lose its Leadership in Asthma Targeted Therapies, Says FirstWord in Its Research Study Published at MarketPublishers.com

28 Apr 2017 • by Natalie Aster

LONDON – At present, Xolair occupies a position of the first-line-therapy for allergic asthma patients who have elevated serum IgE levels. Still, it may lose this position in the near term, as other treatment options may be a better strategy for some patients. Cinqair and Nucala are some of the threats to the leader.

Nucala is set to become the first mAb that will receive approval for severe asthma soon. anti-IL5 mAbs are in different development stages (e.g. benralizumab).

Xolair biosimilars are currently under development, and they may be introduced to some markets by 2018.

In-demand research report “Targeted Therapies in Asthma [2017]” worked out by FirstWord offers a comprehensive discussion of the world’s market for targeted therapies in asthma. The study starts with a detailed overview of the global marketplace.

It insightfully explores marketed products and focuses on pipeline products. The report sheds light on the current treatment algorithm and covers future options. The research study contains quotes of key KOLs from Europe and North America.

Report Highlights:

  • comprehensive overview of the global marketplace;
  • insights into marketed and pipeline products;
  • discussion of the current and future treatment algorithm;
  • and more.

Other Markets Examined by FirstWord Comprise:

More cutting-edge studies by FirstWord can be found at its page

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com